 Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Drug Combinations, Antineoplastic
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
- Combined Antineoplastic Agents
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Combined Chemotherapy Regimens
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Chemotherapy Protocols, Antineoplastic
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 2 | 2 | 4 | | 1985 | 4 | 1 | 5 | | 1986 | 7 | 1 | 8 | | 1987 | 2 | 1 | 3 | | 1988 | 5 | 2 | 7 | | 1989 | 3 | 1 | 4 | | 1990 | 0 | 3 | 3 | | 1991 | 1 | 2 | 3 | | 1992 | 2 | 2 | 4 | | 1993 | 4 | 0 | 4 | | 1994 | 5 | 2 | 7 | | 1995 | 2 | 3 | 5 | | 1996 | 9 | 1 | 10 | | 1997 | 6 | 2 | 8 | | 1998 | 5 | 1 | 6 | | 1999 | 6 | 1 | 7 | | 2000 | 8 | 2 | 10 | | 2001 | 6 | 1 | 7 | | 2002 | 1 | 0 | 1 | | 2003 | 10 | 3 | 13 | | 2004 | 4 | 5 | 9 | | 2005 | 9 | 5 | 14 | | 2006 | 7 | 3 | 10 | | 2007 | 6 | 2 | 8 | | 2008 | 8 | 4 | 12 | | 2009 | 9 | 2 | 11 | | 2010 | 4 | 3 | 7 | | 2011 | 12 | 2 | 14 | | 2012 | 4 | 1 | 5 | | 2013 | 5 | 2 | 7 | | 2014 | 7 | 2 | 9 | | 2015 | 7 | 2 | 9 | | 2016 | 6 | 3 | 9 | | 2017 | 9 | 3 | 12 | | 2018 | 7 | 1 | 8 | | 2019 | 9 | 3 | 12 | | 2020 | 4 | 5 | 9 | | 2021 | 8 | 8 | 16 | | 2022 | 1 | 3 | 4 | | 2023 | 1 | 6 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzm?n A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, Olszewski AJ. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood Adv. 2023 09 12; 7(17):5038-5046.
-
Shouse G, Kaempf A, Gordon MJ, Artz A, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023 Jul 25; 7(14):3516-3529.
-
Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM. Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2023 09; 64(9):1579-1582.
-
Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023 06 13; 7(11):2287-2296.
-
Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, Karmali R, Pro B, Kane KL, Bazzi LA, Chmiel JS, Palmer BA, Mehta J, Gordon LI, Winter JN. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA Oncol. 2023 05 01; 9(5):683-691.
-
David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Chang J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023 06; 98(6):900-912.
-
Gordon LI, Karmali R, Kaplan JB, Popat R, Burris HA, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau FI, Radford J, de Oteyza JP, Zinzani PL, Iyer SP, Townsend W, Miao H, Proscurshim I, Wang S, Katyayan S, Yuan Y, Zhu J, Stumpo K, Shou Y, Carpio C, Bosch F. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget. 2023 01 26; 14:57-70.
-
Nadeem O, Mateos MV, Efebera YA, Paner A, Larocca A, Rodr?guez-Otero P, Leleu X, Richardson PG. Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs Today (Barc). 2022 Aug; 58(8):407-423.
-
Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 10 01; 40(28):3289-3300.
-
Modi S, Giri B, Gupta VK, Lavania S, Sethi V, Sharma NS, Pandey S, Vickers S, Dudeja V, Saluja AK. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. Cancer Lett. 2022 07 01; 537:215591.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|